Navigation Links
Kosan Presents Preclinical Antitumor and Safety Data On,Next-Generation Epothilone KOS-1803 at AACR

HAYWARD, Calif., April 16, 2007 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated today presented preclinical data on KOS-1803, a next-generation epothilone, showing a high level of antitumor activity and a favorable pharmacokinetic and safety profile in a broad range of in vitro tests and in vivo cancer models. KOS-1803 has been chemically engineered to have a favorable tissue distribution pattern, which has been shown in models to result in excellent tumor penetration and a low side effect profile. In human tumor xenograft models, KOS-1803 has demonstrated antitumor activity in breast, lung, prostate and colorectal cancers, as well as in ovarian cancer and neuroblastoma where the extent and duration of tumor regression was curative. Kosan is currently advancing KOS-1803 through later-stage preclinical studies with the potential for future clinical development of the compound.

"KOS-1803 is an exciting, next-generation clinical candidate based on Kosan's proprietary epothilone D backbone that is demonstrating excellent potency and antitumor activity in multiple in vivo cancer models and in taxane-sensitive and resistant cancer cell lines," said Robert G. Johnson, Jr., M.D., Ph.D., Kosan's President and Chief Executive Officer. "KOS-1803 is particularly interesting due to its ability to induce tumor regression, activity at low doses, infrequent dosing schedule and attractive safety profile demonstrated in multiple xenograft models. Our development partner, Roche, and we expect that our lead epothilone compound, KOS-1584 (R1645), will enter Phase 2 trials in solid tumors later in 2007. KOS-1803 may represent a future opportunity to expand the therapeutic and commercial value of our companies' epothilone franchise."

Kosan's epothilone program is partnered with Roche through a global development and commercialization agreement in the area of cancer. In early 2007, Roche and Kosan announced the
'"/>




Page: 1 2 3

Related medicine technology :

1. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
2. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
3. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
4. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
5. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
6. Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR
7. Kosan Announces Data Presentations at Upcoming AACR Annual Meeting
8. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
9. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
10. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
11. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference

Post Your Comments:
(Date:11/25/2009)...stCall/--ERT(Nasdaq: ERES ),announcedtodaythatDr.M...ithSchneck,theCompany,sExecutiveVicePresidentandCF...HealthCareConferenceat1:30PMESTonDecember1,2009inN...ssthepresentationbyvisitingtheCompany,scorporatewe...essedat http://www.corporate-ir.net/ireye/conflobb...
(Date:11/25/2009)...USNewswire/--RemediumTechnologiesInc.,acompanydeve...g,wonfirstprizeand$10,000intheMostPromisingSecurit...anyofficialsannouncetoday. ,, Selectedfrommoret...hedtheirinventionattheGSCSecuritySummitconferenceh...w.remediumtechnologies.com )isdevelopingahigh-pres...
(Date:11/25/2009)...linker.comannouncesthatanewmarketresearchreportisa...nt-AGlobalMarketPerspective ,, http://www.re...Global-Market-Perspective.html ,, Risingincide...gnationsisaprincipalfactorinfluencinggrowthinthema...reastcancerhasallowedwomentocomeforwardfortheiryea...
Breaking Medicine Technology:ERT to Present at the 21st Annual Piper Jaffray Health Care Conference on December 1, 2009 2Remedium Technologies Wins Most Promising Security Idea at Global Security Challenge 2009 with Blood-Clotting Foam 2Remedium Technologies Wins Most Promising Security Idea at Global Security Challenge 2009 with Blood-Clotting Foam 3Reportlinker Adds Mammography Equipment - A Global Market Perspective 2Reportlinker Adds Mammography Equipment - A Global Market Perspective 3Reportlinker Adds Mammography Equipment - A Global Market Perspective 4Reportlinker Adds Mammography Equipment - A Global Market Perspective 5Reportlinker Adds Mammography Equipment - A Global Market Perspective 6Reportlinker Adds Mammography Equipment - A Global Market Perspective 7Extending treatment after liver transplant may benefit patients with hepatitis C recurrence 60452 1Extending treatment after liver transplant may benefit patients with hepatitis C recurrence 60452 2Toronto Conference Targets the Vitamin D Deficiency Crisis 60448 1Toronto Conference Targets the Vitamin D Deficiency Crisis 60448 2Toronto Conference Targets the Vitamin D Deficiency Crisis 60448 3BYETTA Approved for Expanded Use as First Line Treatment for Type 2 Diabetes 14673 1BYETTA Approved for Expanded Use as First Line Treatment for Type 2 Diabetes 14673 2BYETTA Approved for Expanded Use as First Line Treatment for Type 2 Diabetes 14673 3BYETTA Approved for Expanded Use as First Line Treatment for Type 2 Diabetes 14673 4BYETTA Approved for Expanded Use as First Line Treatment for Type 2 Diabetes 14673 5BYETTA Approved for Expanded Use as First Line Treatment for Type 2 Diabetes 14673 6BYETTA Approved for Expanded Use as First Line Treatment for Type 2 Diabetes 14673 7
...tro Assays Show rBChE Suppresses Amyloid Plaque,Fo...ene, Inc., a leading,biodefense company specializi...ical countermeasures against chemical and,biologic...ts,recombinant butyrylcholinesterase (rBChE) resea...ernational Conference on,Alzheimer,s and Parkinson...
...T, N.J., April 04, 2007 /PRNewswire-FirstCall/ -- ...perative Oncology Group,(ECOG) has reported that i...liminary results from a large, randomized clinical...myeloma has found,that the use of a low dose of de...omide suggests survival advantage for,patients whe...
Other Medicine Technology:Pharmathene's Recombinant Butyrylcholinesterase (rBChE) Program the,Subject of Promising New Alzheimer's Research 2Pharmathene's Recombinant Butyrylcholinesterase (rBChE) Program the,Subject of Promising New Alzheimer's Research 3Pharmathene's Recombinant Butyrylcholinesterase (rBChE) Program the,Subject of Promising New Alzheimer's Research 4Pharmathene's Recombinant Butyrylcholinesterase (rBChE) Program the,Subject of Promising New Alzheimer's Research 5Pharmathene's Recombinant Butyrylcholinesterase (rBChE) Program the,Subject of Promising New Alzheimer's Research 6ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03),Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival,Advantage for Patients with Multiple Myeloma 2ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03),Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival,Advantage for Patients with Multiple Myeloma 3ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03),Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival,Advantage for Patients with Multiple Myeloma 4ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03),Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival,Advantage for Patients with Multiple Myeloma 5ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03),Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival,Advantage for Patients with Multiple Myeloma 6ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03),Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival,Advantage for Patients with Multiple Myeloma 7
(Date:11/27/2009)...alth™ announced today that Spectrum Health (... Enterprise orthopedic templating solution and its... (PRWEB) November 27, 2009 -- Voyant ... (Grand Rapids, Michigan) has licensed its TraumaC...ts TraumaCad Extend workflow solution, to allow it...
(Date:11/26/2009)...-Withcoldandfluseasonuponus,it,smoreimportantthane...ionsandavoidillness. ,, "Weneedtobeproactivenot...llnessifwe,resick,"saidEileenFinerty,RN,MS,CIC(cer...tioncontrolandoccupationalhealthatHospitalforSpeci...lSurgeryhasoneofthelowestinfectionratesofanyhospit...
(Date:11/26/2009)... can lead to strains or worse , , THURSD...ng wrong with stuffing your turkey full to burstin...h your suitcase as you pack for holiday trips. ,...U.S. hospital emergency rooms, doctors, offices, c...lated injuries, such as muscle strains, pulls and ...
(Date:11/26/2009)...Triangle Dental (RTDental), a leading dental group...ed the expansion of its services to include LUMINE...illan. , Durham, NC (P...nounce that Dr. Doug Macmillan, an experienced LU... advanced training seminar. RTDental’s abil...
(Date:11/25/2009)...swire/--TheBartleHallConventionCenterwilltemporari...whenKansasCityhoststhelatestinaseriesofmassivefree...enthasthepotentialtobethebiggestoneyet,becauseitwi...daysinsteadofoveraweekend,"SheriWood,executivedire...heNationalAssociationofFreeClinics(NAFC). ,, At...
Breaking Medicine News(10 mins):Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 3Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 2Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 3Health News:Pack Right for the Holidays to Avoid the ER 2Health News:Dr. Douglas Macmillan Now Providing LUMINEERS at Research Triangle Dental 2Health News:Kansas City Prepares for Largest Free Health Clinic 2
... addresses health disparities in children; adolesc...tion for Quality Healthcare announced today that i...ity Health Centers, Inc. (MCCHC) in Alexandria, I... children. , , The program focuses on conducting ...
...r Human Rights responds to the publication of a l...e Red Cross which concludes that health profession...et detention centers committed gross violations of... confidential International Committee of the Red C...
... ETS EXPOSURE , Environmental tobacco smoke (ETS) ...n children. However, a new study shows that reduci...iversity of Alabama researchers followed 240 child...ded to caregivers; however, children were given 20...
... of African American employees , , GAITHERSBURG,...xo, a leading integrated food and facilities manag...t who I am as an African American and a woman and ... African American Leadership Forum network group. ...
...he comScore, Inc. February rankings, Health Guru M... growing health site on the web over the last thre...o one of the few health sites with more video view...ruary rankings, Health Guru Media (HealthGuru.com)...
...lp facilitate dialogue,during an eye examination b...Hispanic patients, Transitions Optical has develop...his free bilingual guide illustrates key steps tha...n,critical to making the best possible recommendat...
Other Medicine News:Health News:Centene Foundation for Quality Healthcare Awards Grant to Community Health Center 2Health News:In Wake of ICRC Report, Health Professionals Must Be Held Accountable for Torture 2Health News:In Wake of ICRC Report, Health Professionals Must Be Held Accountable for Torture 3Health News:Journal Chest: April news briefs 2Health News:Sodexo Named as One of the Top Three Companies for African Americans on 2009 DiversityInc Top Ten Companies List 2Health News:Web's Fastest Growing Health Site is a Video Site 2Health News:Web's Fastest Growing Health Site is a Video Site 3Health News:Free Bilingual Eye Exam Guide Now Available to Eyecare Professionals 2Health News:Free Bilingual Eye Exam Guide Now Available to Eyecare Professionals 3
...BAK/C cervical interbody fusion system represents ...ive disc disease of the cervical spine. The system...ration, and implantation. The self-packing of bone...raft, eliminating the need to harvest from the ili...
Intera 3.0T
...The Intradiscal Instruments are designed to provid...sc removal, endplate preparation, and insertion of...tebral Spreaders, Intradiscal Wedges, Spanners, Ne...er. Used in ALIF (Anterior Thoracic Interbody Fusi...
...Symphony II Platelet Concentrate System is a point... of Platelet Concentrate (also referred to as Plat...PPP) from a small sample of blood. The Symphony II...s, which are found in the platelets. The platelet ...
Medicine Products: